The Primacy of Public Health Considerations in Defining Poor Quality Medicines

  • Newton P
  • Amin A
  • Bird C
  • et al.
N/ACitations
Citations of this article
116Readers
Mendeley users who have this article in their library.

Abstract

Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.

Cite

CITATION STYLE

APA

Newton, P. N., Amin, A. A., Bird, C., Passmore, P., Dukes, G., Tomson, G., … White, N. J. (2011). The Primacy of Public Health Considerations in Defining Poor Quality Medicines. PLoS Medicine, 8(12), e1001139. https://doi.org/10.1371/journal.pmed.1001139

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free